EN
RU
EN

Point of Care

The developed automatic station standardizes and reduces the duration of direct human involvement in the process of CAR-T cells production, as well as increases reproducibility. As a result, the CAR-T therapy can be provided to a larger number of people.

Product
BackgroundImage

From Sketch to Scale

Correction of defects caused by changes in the structure of DNA or DNA damages of viral etiology, changing of cell functions is a new and rapidly developing field of gene engineering. The Point оf Care station was designed for adoptive cellular immunotherapy (ACI) carried out by transfer of Т-cells. ACI includes ex vivo expansion of tumor cell-specific T-cells and further reinfusion into a patient’s organism. According to the experts’ point of view, this therapy is one of the most promising methods discovered over the past decade allowing to overcome oncological and autoimmune diseases.

Scroll down